Press Releases

23 Jun

Posted at 07:58h in Poster and Presentations, Poster and Presentations 2020

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="/wp-content/uploads/AACR20_VMII_Presentation_AMV564_Monotherapy_Solid_Tumor_AML-MDS.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...

23 Jun

Posted at 07:09h in Press Releases, Press Releases 2020

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] AMV564, a novel first-in-class agent that depletes MDSC and polarizes T cells, is being investigated in Ph1 clinical trials in advanced solid tumors and hematological cancers and is well tolerated with single-agent activity across both solid and...

17 Jun

Posted at 12:48h in Press Releases, Press Releases 2020

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – June 17, 2020 -- Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today announced that it will present translational data for its lead clinical candidate, AMV564, a...

29 May

Posted at 06:07h in Press Releases, Press Releases 2020

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities AMV564 showed single-agent activity including one complete response in a...

28 May

Posted at 21:42h in Poster and Presentations

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="/wp-content/uploads/ASCO2020_Poster_Draft_final.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...

14 May

Posted at 07:00h in Press Releases, Press Releases 2020

SOUTH SAN FRANCISCO, CA – May 14, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity to the patient, today announced that the first clinical data from the phase 1 study to evaluate its lead therapeutic candidate, AMV564,...

09 Dec

Posted at 10:36h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – (Business Wire) -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase...

07 Dec

Posted at 07:25h in Poster and Presentations

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="/wp-content/uploads/AMV564-ASH-2019-Presentation-Final-2019-12-04.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...

02 Dec

Posted at 07:00h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – December 2, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its...

07 Nov

Posted at 11:59h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors South San Francisco, CA – November 7, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, will present at...

07 Nov

Posted at 08:20h in Poster and Presentations

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="/wp-content/uploads/Amphivena-Presentaton-SITC2019-O71v2-20191107.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...

01 Nov

Posted at 08:35h in Poster and Presentations

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="/wp-content/uploads/Amphivena-Poster-20191106-SITC2019-Poster_AMV564-301_Print-Version_1Nov2019.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][vc_empty_space height="100px"][/vc_column][/vc_row]...

16 Oct

Posted at 08:58h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors South San Francisco, CA -- October 16, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell...

24 Sep

Posted at 08:00h in Poster and Presentations 2019, Press Releases

South San Francisco, CA —September 24, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners...

01 Jul

Posted at 08:00h in Press Releases, Press Releases 2019

South San Francisco, CA – July 1, 2019 -- Amphivena Therapeutics, Inc., highlighted initial data from the dose escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML, AMV564-101, NCT03144245) in an oral presentation June...

05 Jun

Posted at 08:36h in Poster and Presentations

[tnc-pdf-viewer-iframe file="https://amphivena.com/wp-content/uploads/2019-Amphivena-presentation-S877_Safety_and_Clinical_Activity_AMV564_Roboz_EHA_2019-Presentation.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=“"]...

05 Mar

Posted at 21:57h in Press Releases, Press Releases 2019

[fluid][html css="margin-top:23px;"] SOUTH SAN FRANCISCO – March 5, 2019 -- Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief...